Psilocybin Microdosing Protocols: Fadiman vs Stamets vs Every Day

The Short Answer

The three most common microdosing protocols are: **Fadiman** (1 day on, 2 days off — the most studied), **Stamets** (4 days on, 3 days off — includes lion\'s mane and niacin), and **Every Day** (daily — not recommended due to rapid tolerance development). The Fadiman protocol is the most commonly recommended starting point because it allows clear comparison between microdosing and non-microdosing days, prevents tolerance, and has the most observational data.

Protocol Comparison

Protocol	Schedule	Dose	Best For
Fadiman	Day 1 on, Day 2-3 off	0.1–0.3g	General use, beginners
Stamets	4 days on, 3 days off	0.1–0.2g + lion\'s mane + niacin	Neuroplasticity, cognitive enhancement
Every Day	Daily	0.05–0.1g	Not recommended (tolerance)
Intuitive	As needed	Variable	Experienced users only

The Fadiman Protocol

Developed by James Fadiman based on observational data from hundreds of self-reporters. The 1-on, 2-off schedule prevents tolerance (psilocybin tolerance develops within 24–48 hours) and allows clear comparison between microdosing and non-microdosing days for tracking effects.

The Stamets Protocol

Developed by mycologist Paul Stamets. Adds lion\'s mane mushroom (for NGF stimulation) and niacin (as a "flush" to drive the compounds into the nervous system) to psilocybin. The 4-on, 3-off schedule is more aggressive. Stamets claims synergistic neuroplasticity effects from the combination.

Which Protocol to Start With

For most people, the Fadiman protocol is the best starting point. It is the most studied, the most forgiving, and provides the clearest feedback on effects. Start at 0.1g and adjust based on response. [See the full protocol →](/research-checkout) *This article is for informational purposes only and does not constitute medical advice.*

Understanding the Fadiman Protocol: A Deeper Dive

The Fadiman Protocol, named after pioneering psychedelic researcher Dr. James Fadiman, is arguably the most recognized and widely adopted microdosing regimen [Fadiman, 2011]. Its popularity stems from its simplicity, effectiveness in mitigating tolerance, and the extensive anecdotal data collected over years. The core of this protocol involves taking a microdose of a psychedelic substance, typically psilocybin, once every three days. This means one day on, followed by two days off, before the next dose [Fadiman & Korb, 2019].

The Rationale Behind the 1-on, 2-off Schedule

The primary reason for the two-day break in the Fadiman protocol is to prevent the rapid development of tolerance to psilocybin. Research indicates that tolerance to psychedelics can develop within 24-48 hours of use [Passie, 2019]. By introducing two off-days, the protocol ensures that the body\'s serotonin receptors have sufficient time to reset, allowing each subsequent microdose to have a consistent, subtle effect without requiring an increased dosage. This schedule also provides an opportunity for individuals to observe the effects of microdosing on both dosing and non-dosing days, facilitating a clearer understanding of its impact on their mood, cognition, and overall well-being [Fadiman, 2011].

Observed Benefits and Research Insights

Dr. Fadiman\'s initial work involved collecting self-reports from hundreds of individuals who followed his protocol. These observational studies, while not always double-blind or placebo-controlled, provided a wealth of qualitative data suggesting various benefits. Participants frequently reported improvements in mood, increased energy levels, enhanced creativity, and improved focus [Fadiman & Korb, 2019]. Some also noted a reduction in symptoms associated with depression and anxiety, as well as alleviation of conditions like migraine headaches and pre-menstrual syndromes [Fadiman & Korb, 2019]. More recent systematic reviews, such as one published in *Neuroscience and Biobehavioral Reviews* in 2022, have synthesized findings from 44 studies on microdosing. While acknowledging the exploratory and observational nature of much of the research, this review found emerging evidence of possible improvements in mental health, substance use disorders, and psychological functioning [Polito & Liknaitzky, 2022]. Specifically, microdosing was regularly associated with improvements in depression in uncontrolled observational studies, and some studies indicated increases in creativity [Polito & Liknaitzky, 2022]. It\'s important to note that the scientific community is still actively investigating the precise mechanisms and efficacy of microdosing. A double-blind placebo-controlled study on psilocybin microdosing, published in *Translational Psychiatry* in 2022, found that while low doses of psilocybin mushrooms could result in noticeable subjective effects and altered EEG rhythms, there was no conclusive evidence to support enhanced well-being, creativity, and cognitive function in all participants, suggesting that expectation might play a role in perceived benefits [Cavanna et al., 2022]. However, this study also highlighted the challenges of conducting microdosing research in standard laboratory settings, which may not fully capture the motivations and real-world experiences of individuals engaging in microdosing protocols.

Practical Application of the Fadiman Protocol

For those considering the Fadiman protocol, the recommended dosage for psilocybin mushrooms typically ranges from 0.1 to 0.3 grams of dried material [Fadiman, 2011]. It is crucial to start with a lower dose and gradually adjust based on individual response, always aiming for a sub-perceptual effect – meaning no noticeable psychedelic effects. The protocol is often followed for a period of 4-8 weeks, followed by a break of similar duration to further assess the effects and prevent long-term tolerance [Microdosing Institute]. This cyclical approach allows for integration of insights gained during microdosing periods and helps maintain the efficacy of the regimen. Happy Shrooomz offers a range of resources for those interested in exploring functional mushrooms and understanding microdosing practices responsibly.

For further reading on microdosing for mental health, consider these resources:

• Microdosing Mushrooms for Depression
• Microdosing Mushrooms for Anxiety
• Psilocybin Neuroplasticity: How Mushrooms Rewire the Brain

The Stamets Protocol: Stacking for Enhanced Neurogenesis

Another prominent microdosing regimen, gaining significant attention, is the Stamets Protocol, often referred to as the "Stamets Stack." Developed by renowned mycologist Paul Stamets, this protocol combines a microdose of psilocybin with two other natural compounds: Lion\'s Mane mushroom (*Hericium erinaceus*) and Niacin (Vitamin B3) [Rootman et al., 2022]. The rationale behind this synergistic combination is to potentially amplify the neurogenic and cognitive-enhancing effects of psilocybin.

Components of the Stamets Stack and Their Proposed Roles

The Stamets Stack is built upon three key ingredients, each believed to contribute uniquely to the overall effect:

Component	Proposed Role/Benefits	Scientific Basis (where available)
**Psilocybin (Microdose)**	Promotes neuroplasticity, mood enhancement, and cognitive flexibility.	Animal studies suggest psilocybin can encourage neural plasticity and help "reset" brain patterns [Medical News Today, 2022]. Human observational studies link microdosing to improved mood and mental health [Rootman et al., 2022].
**Lion\'s Mane Mushroom (*Hericium erinaceus*)**	Supports neurogenesis (growth of new brain cells) and nerve growth factor (NGF) production.	Compounds like hericenones and erinacines stimulate NGF, which helps grow and repair nerve cells. A 2009 clinical trial showed improvements in mild cognitive impairment after 16 weeks of Lion’s Mane supplementation [Medical News Today, 2022]. Preclinical evidence suggests facilitation of neurogenesis [Rootman et al., 2022].
**Niacin (Vitamin B3)**	Believed to enhance circulation, facilitating the delivery of psilocybin and Lion\'s Mane compounds to the brain.	Expands blood vessels, potentially improving the bioavailability of other compounds. Plays a role in DNA repair and cell energy metabolism [Medical News Today, 2022].

The Dosing Schedule and Reported Effects

The typical Stamets Protocol involves a microdose of psilocybin, Lion\'s Mane, and Niacin for 4-5 consecutive days, followed by 2-3 days off. This cycle is then repeated for 4-6 weeks, after which a break of 2-6 weeks is recommended [Aeon, 2024]. This schedule aims to maximize the potential benefits while allowing for periods of integration and preventing tolerance buildup. Anecdotal reports and some observational studies suggest that individuals following the Stamets Stack experience enhanced focus, improved mood, increased creativity, and overall brain health benefits [eatmomushrooms.com, 2025]. A study published in *Scientific Reports* in 2022, co-authored by Paul Stamets, found that among older microdosers, combining psilocybin with Lion\'s Mane and Niacin was associated with psychomotor improvements relative to psilocybin alone or psilocybin with Lion\'s Mane [Rootman et al., 2022]. This suggests a potential synergistic effect, particularly for certain cognitive functions in older adults.

Scientific Scrutiny and Future Research

While the theoretical basis and anecdotal evidence for the Stamets Stack are compelling, it is important to note that, as of now, there are **no published clinical trials** specifically investigating the combined effects of all three components of the Stamets Stack in a controlled setting [eatmomushrooms.com, 2025]. Most findings are derived from research on the individual ingredients or from observational studies where participants self-report their experiences. The *Scientific Reports* study, while significant, was naturalistic and observational, and the authors themselves highlighted the need for further research to confirm and elucidate these apparent effects [Rootman et al., 2022]. The proposed mechanism of Niacin enhancing the delivery of other compounds via vasodilation is a hypothesis that requires rigorous scientific validation. Similarly, the idea of "super-additive effects" from combining psilocybin and Lion\'s Mane, both of which are proposed to operate via BDNF-related processes, remains an area for future experimental investigation [Rootman et al., 2022]. Despite the current lack of comprehensive clinical trials on the stack as a whole, the individual components—psilocybin and Lion\'s Mane—continue to be subjects of extensive research for their respective therapeutic potentials. For those interested in exploring cognitive enhancement and neurogenesis, Happy Shrooomz offers high-quality functional mushroom products, including Lion\'s Mane, which can be incorporated into a wellness routine.

For more information on the individual components and related topics, consider these links:

• Lion\'s Mane Mushroom Benefits Research
• Lion\'s Mane and Brain Fog
• Psilocybin Neuroplasticity: How Mushrooms Rewire the Brain

Exploring Other Microdosing Protocols: Daily and Intuitive Approaches

Beyond the structured Fadiman and Stamets protocols, other microdosing approaches exist, including daily microdosing and more intuitive methods. While these may appeal to some for their perceived simplicity or flexibility, it is crucial to understand the scientific perspectives and potential drawbacks associated with them.

Daily Microdosing: A Cautious Approach

The concept of daily microdosing involves taking a sub-perceptual dose of a psychedelic substance every day. The primary motivation for this approach is often to maintain a consistent level of perceived benefits, such as improved mood, focus, or creativity. However, this method is generally **not recommended** by experts and researchers in the field [Aeon, 2024]. The main concern with daily microdosing is the rapid development of **tolerance** to psychedelic substances. Psilocybin, for instance, can lead to tolerance within a few days of consecutive use, meaning that the same dose will produce diminishing effects over time [Polito, 2019]. To counteract this, individuals might be tempted to increase their dosage, which can elevate the risk of experiencing unwanted psychoactive effects, disrupting the sub-perceptual nature of microdosing, and potentially leading to a full psychedelic experience. Furthermore, continuous daily use may also increase the likelihood of other adverse effects, though research in this area is still emerging [Aeon, 2024]. Most established microdosing protocols, like the Fadiman and Stamets methods, incorporate regular breaks precisely to prevent tolerance and allow the body and mind to reset. This cyclical approach is considered a safer and more sustainable way to engage with microdosing.

Intuitive Microdosing: Listening to Your Body

Intuitive microdosing is a less structured approach where individuals take microdoses based on their perceived needs or feelings, rather than adhering to a strict schedule. This might involve microdosing on days when one anticipates a demanding cognitive task, feels a dip in mood, or seeks a creative boost. The core idea is to listen to one\'s body and mind, using the microdose as a tool when it feels most beneficial. While intuitive microdosing offers flexibility, it also presents challenges. The lack of a consistent schedule can make it difficult to objectively track the effects of microdosing and distinguish them from other daily variables. Without a structured approach, it can be harder to determine optimal dosing frequencies and to identify potential patterns in how microdosing impacts an individual. Moreover, the subjective nature of this approach means it relies heavily on self-awareness and careful self-assessment, which can be influenced by expectation and placebo effects [Cavanna et al., 2022]. Currently, there is limited scientific research specifically on intuitive microdosing protocols. Most studies on microdosing have focused on structured regimens, making it difficult to draw definitive conclusions about the efficacy or safety of intuitive approaches. Individuals considering intuitive microdosing are encouraged to maintain a detailed journal to record their dosages, experiences, and any observed changes to help bring some structure and objectivity to their practice.

General Science of Microdosing: Underlying Mechanisms

Regardless of the specific protocol, the general science behind microdosing revolves around the interaction of psychedelic compounds, primarily psilocybin, with the brain\'s serotonin system. Psilocybin is a prodrug that is converted to psilocin in the body, which then acts as a partial agonist at serotonin 5-HT2A receptors [Nichols, 2016]. These receptors are widely distributed throughout the brain and play a crucial role in mood, perception, and cognition. At sub-perceptual doses, psilocybin is thought to modulate neural activity in ways that can lead to subtle yet beneficial changes. Proposed mechanisms include: * **Enhanced Neuroplasticity:** Emerging research suggests that microdosing psychedelics may promote neuroplasticity, the brain\'s ability to form and reorganize synaptic connections [Daytryp, 2025]. This could contribute to improved learning, adaptability, and the ability to break free from rigid thought patterns often associated with conditions like depression and anxiety [Carhart-Harris & Goodwin, 2017]. * **Modulation of Brain Networks:** Studies using fMRI have shown that even low doses of psychedelics can alter functional connectivity between different brain regions, particularly those involved in the default mode network (DMN). A reduction in DMN activity and increased connectivity between other networks is hypothesized to contribute to enhanced creativity and a more open state of consciousness [Carhart-Harris et al., 2012]. * **Anti-inflammatory Effects:** Some preclinical research indicates that certain psychedelic compounds may possess anti-inflammatory properties, which could indirectly contribute to mental health benefits, as inflammation is increasingly linked to mood disorders [Irwin & Miller, 2007]. * **Increased Serotonin Activity:** By subtly stimulating 5-HT2A receptors, microdoses may lead to a gentle upregulation of serotonin pathways, potentially contributing to improved mood and emotional regulation without the overwhelming effects of a full dose [Nichols, 2016]. While the exact mechanisms are still under investigation, the growing body of research points towards microdosing as a promising area for understanding consciousness, mental health, and cognitive enhancement. Happy Shrooomz is committed to supporting research and providing accurate information on the responsible use of functional mushrooms and the science behind microdosing.

For further reading on the science of microdosing and related topics:

• Psilocybin Neuroplasticity: How Mushrooms Rewire the Brain
• Microdosing vs. Antidepressants: Side Effects
• Psilocybin Clinical Trials: Depression Results

Important Considerations for Psilocybin Microdosing

Engaging in psilocybin microdosing, regardless of the chosen protocol, necessitates a thorough understanding of its potential benefits, inherent risks, and the evolving legal landscape. A responsible approach involves careful consideration of these factors to ensure safety and maximize potential positive outcomes.

Potential Benefits: A Glimpse into Enhanced Well-being

While research on microdosing is still in its nascent stages, a growing body of anecdotal evidence and preliminary scientific studies suggest several potential benefits. These reported advantages often span across psychological, emotional, and cognitive domains: * **Improved Mood and Mental Health:** Many microdosers report a reduction in symptoms of depression and anxiety, along with an overall enhancement in mood and emotional well-being [Rootman et al., 2022; Health Harvard, 2022]. Some studies indicate that microdosing can lead to greater observed improvements in mood and mental health compared to non-microdosing controls [Rootman et al., 2022]. * **Enhanced Creativity and Cognitive Function:** Users frequently describe increased creativity, improved problem-solving abilities, and enhanced focus and concentration [Cavanna et al., 2022; Health Harvard, 2022]. This is often attributed to the neuroplastic effects of psilocybin, which may facilitate new neural connections and more flexible thinking patterns. * **Increased Energy and Productivity:** Many individuals report higher energy levels and improved work effectiveness, leading to greater productivity in their daily tasks [Fadiman & Korb, 2019]. * **Greater Empathy and Openness:** Some anecdotal accounts suggest an increase in empathy, openness, and a deeper connection with others and their surroundings [Health Harvard, 2022]. It is important to reiterate that while these benefits are frequently reported, the scientific community is still working to differentiate pharmacological effects from placebo effects, as expectations can significantly influence perceived outcomes in microdosing [Szigeti et al., 2021].

Potential Risks and Side Effects: Navigating the Unknowns

Despite the promising aspects, microdosing psilocybin is not without potential risks and side effects. Responsible practice requires an awareness of these concerns: * **Cardiac Valvulopathy (Heart Valve Damage):** One of the most significant theoretical concerns with long-term, repeated microdosing of serotonergic psychedelics is the potential for cardiac valvulopathy, or damage to heart valves [Healthy Life Recovery, n.d.; Petrie-Flom Center, 2022]. This concern stems from the fact that psilocybin interacts with 5-HT2B serotonin receptors, and some medications that activate these receptors have been linked to heart valve issues. While direct evidence linking microdosing to VHD in humans is currently lacking, the theoretical risk warrants caution and further research. * **Increased Anxiety and Agitation:** Paradoxically, some individuals report increased anxiety, agitation, or paranoia, especially if the dose is too high or if they have pre-existing anxiety disorders [Medical News Today, 2022; BrainFacts.org, 2020]. * **Physical Discomfort:** Other reported side effects can include mild physical discomforts such as nausea, changes in body temperature, or headaches [Healthline, 2024]. * **Psychological Distress:** While rare at microdoses, there is a theoretical risk of triggering or exacerbating underlying psychological conditions, particularly in individuals with a personal or family history of psychosis or bipolar disorder [Aeon, 2024]. * **Lack of Regulation and Purity Concerns:** As psilocybin remains largely illegal, products obtained from unregulated sources may vary significantly in potency and purity, posing risks of accidental overdose or exposure to contaminants [Aeon, 2024].

The Legal Landscape of Psilocybin Microdosing

The legal status of psilocybin is complex and rapidly evolving, varying significantly by jurisdiction. Federally, in the United States, psilocybin is classified as a Schedule I controlled substance, indicating a high potential for abuse and no currently accepted medical use [DEA, n.d.]. This federal prohibition makes the possession, sale, and cultivation of psilocybin illegal. However, there is a growing movement towards decriminalization and legalization at state and local levels: * **Oregon:** In 2020, Oregon became the first state to decriminalize possession of all drugs, including psilocybin, and established a framework for regulated psilocybin services [Recovered.org, 2025]. * **Colorado:** In 2022, Colorado followed suit, decriminalizing psilocybin and other natural psychedelics for personal use and creating a system for regulated access in licensed healing centers [Colorado Springs Criminal Defense, n.d.]. * **Other Jurisdictions:** Numerous other cities and states across the U.S. have passed measures to decriminalize psychedelics, often prioritizing naturally occurring substances like psilocybin mushrooms [Psychedelic Alpha, n.d.]. Despite these changes, it is crucial to understand that decriminalization does not equate to full legalization, and the legal status of microdosing specifically can still be ambiguous in many areas. Individuals considering microdosing should thoroughly research the laws in their specific location and understand the potential legal ramifications. Happy Shrooomz advocates for responsible and legal practices in all aspects of mushroom use.

Frequently Asked Questions About Psilocybin Microdosing Protocols

References

• [Aeon, 2024] Aideyan, T. (2024, April 5). *A nine-step guide to a sensible microdosing programme*. Aeon. Retrieved from https://aeon.co/essays/a-nine-step-guide-to-a-sensible-microdosing-programme
• [BrainFacts.org, 2020] Society for Neuroscience. (2020, June 25). *How Microdosing Psychedelic Drugs Affects Mental Health*. BrainFacts.org. Retrieved from https://www.sfn.org/sitecore/content/home/brainfacts2/diseases-and-disorders/mental-health/2020/how-microdosing-psychedelic-drugs-affects-mental-health-062420
• [Carhart-Harris & Goodwin, 2017] Carhart-Harris, R. L., & Goodwin, G. M. (2017). The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future. *Neuropsychopharmacology, 42*(11), 2105–2113.
• [Carhart-Harris et al., 2012] Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Evans, L., Thaisen, A. A., ... & Nutt, D. J. (2012). Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. *Proceedings of the National Academy of Sciences, 109*(6), 2138–2143.
• [Cavanna et al., 2022] Cavanna, F., Muller, S., de la Fuente, L. A., Zamberlan, F., Palmucci, M., Janeckova, L., ... & Tagliazucchi, E. (2022). Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study. *Translational Psychiatry, 12*(1), 307. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC9346139/
• [Colorado Springs Criminal Defense, n.d.] *A Guide To Recreational Use of Psychedelic Mushrooms in Colorado*. Colorado Springs Criminal Defense. Retrieved from https://coloradospringscriminaldefense.net/guide-recreational-use-psychedelic-mushrooms-in-colorado-new-magic-mushroom-laws/
• [Daytryp, 2025] *Psilocybin Microdosing: A Comprehensive 2025 Guide*. (2025, June 26). Daytryp. Retrieved from https://daytryp.com/psilocybin/psilocybin-microdosing-a-comprehensive-2025-guide/
• [DEA, n.d.] *Drug Scheduling*. U.S. Drug Enforcement Administration. Retrieved from https://www.dea.gov/drug-information/drug-scheduling
• [eatmomushrooms.com, 2025] Haldeman, M. (2025, August 9). *Stacking Lion’s Mane: What the Science Says About the Stamets Stack and Beyond*. Eat Mo Mushrooms. Retrieved from https://www.eatmomushrooms.com/blog-3-1/stacking-lions-mane-what-the-science-says-about-the-stamets-stack-and-beyond
• [Fadiman, 2011] Fadiman, J. (2011). *The Psychedelic Explorer’s Guide: Safe, Therapeutic, and Sacred Journeys*. Park Street Press.
• [Fadiman & Korb, 2019] Fadiman, J., & Korb, S. (2019). Might Microdosing Psychedelics Be Safe and Beneficial? An Initial Exploration. *Journal of Psychoactive Drugs, 51*(2), 118–122. Retrieved from https://www.tandfonline.com/doi/abs/10.1080/02791072.2019.1593561
• [Health Harvard, 2022] Harvard Health Publishing. (2022, September 19). *The popularity of microdosing of psychedelics: What does the science say?* Harvard Medical School. Retrieved from https://www.health.harvard.edu/blog/the-popularity-of-microdosing-of-psychedelics-what-does-the-science-say-202209192819
• [Healthline, 2024] Cherney, K. (2024, June 26). *Beginner’s Guide to Microdosing: Potential Benefits, Risks, and Current Research*. Healthline. Retrieved from https://www.healthline.com/health/beginners-guide-to-microdosing
• [Healthy Life Recovery, n.d.] *Microdosing Psilocybin: The Pros, Cons & Unknowns*. Healthy Life Recovery. Retrieved from https://healthyliferecovery.com/microdosing-psilocybin-the-pros-cons-and-unknowns/
• [Irwin & Miller, 2007] Irwin, M. R., & Miller, A. H. (2007). Stress-induced immune dysregulation: Implications for psychiatric disorders. *JAMA, 298*(14), 1700–1702.
• [Medical News Today, 2022] Shukla, D. (2022, July 25). *Microdoses of psychedelic mushrooms may improve mood and mental health*. Medical News Today. Retrieved from https://www.medicalnewstoday.com/articles/microdoses-of-psychedelic-mushrooms-may-improve-mood-and-mental-health
• [Microdosing Institute] *Microdosing Protocols*. Microdosing Institute. Retrieved from https://microdosinginstitute.com/how-to/microdosing-protocols/
• [Nichols, 2016] Nichols, D. E. (2016). Psychedelics. *Pharmacological Reviews, 68*(2), 264–355.
• [Passie, 2019] Passie, T. (2019). *The Science of Microdosing Psychedelics*. Healing Arts Press.
• [Petrie-Flom Center, 2022] Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School. (2022, April 13). *Safety First: Potential Heart Health Risks of Microdosing*. Retrieved from https://petrieflom.law.harvard.edu/2022/04/13/safety-first-potential-heart-health-risks-of-microdosing/
• [Polito, 2019] Polito, V. (2019). A systematic study of microdosing psychedelics. *PLoS ONE, 14*(2), e0211023. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC6364961/
• [Polito & Liknaitzky, 2022] Polito, V., & Liknaitzky, P. (2022). The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955–2021) and recommendations for the field. *Neuroscience & Biobehavioral Reviews, 139*, 104706. Retrieved from https://www.sciencedirect.com/science/article/pii/S0149763422001956
• [Psychedelic Alpha, n.d.] *Psychedelics Legalization & Decriminalization Tracker*. Psychedelic Alpha. Retrieved from https://psychedelicalpha.com/resources/psychedelic-laws/
• [Recovered.org, 2025] *Psilocybin Legal Status by State and Federal Law 2025*. (2025, April 14). Recovered.org. Retrieved from https://recovered.org/hallucinogens/psilocybin/psilocybin-legal-status
• [Rootman et al., 2022] Rootman, J. M., Kiraga, M., Kryskow, P., Harvey, K., Stamets, P., Santos-Brault, E., ... & Walsh, Z. (2022). Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls. *Scientific Reports, 12*(1), 11091. Retrieved from https://www.nature.com/articles/s41598-022-14512-3
• [Szigeti et al., 2021] Szigeti, B., Rácz, A., Rácz, E., Girlanda, F., Rosas, F. E., Watts, R., ... & Carhart-Harris, R. L. (2021). Self-blinding citizen science to explore psychedelic microdosing. *eLife, 10*, e62878.